← OTSUKA (OTSKF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
OTSUKA (OTSKF)
Healthcare · market cap $38.8B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-20 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Otsuka Holdings (OTSKF) is a large-cap Japanese healthcare conglomerate with approximately 35,338 employees and a market cap of ~$34 billion. The company operates a broad, multi-therapeutic pipeline spanning psychiatry, nephrology, oncology, dermatology, and rare disease, with several Phase 3 assets near read-out. Key near-term catalysts include Phase 3 data for SEP-363856 (schizophrenia) in October 2026, JNT-517 (PKU) in November 2026, and the BPaQM TB regimen in May 2027.
The catalyst path
- 2026-10-20 (est.)Phase 3 · SEP-363856imp 9/10
- 2026-11-01 (est.)Phase 3 · JNT-517 Tabletimp 9/10
- 2027-01-11 (est.)Phase 3 · Delamanid (DLM)imp 9/10
- 2027-03-13 (est.)Phase 2 · Sibeprenlimabimp 7/10
- 2027-05-15 (est.)Phase 2 · IRL757imp 7/10
- 2027-05-27 (est.)Phase 3 · Centanafadine XRimp 9/10
- 2027-05-28 (est.)Phase 3 · BPaQMimp 9/10
- 2027-08-15 (est.)Phase 3 · EB-1020 (Centanafadine) low doseimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Aripiprazole tablet, 10 mg | Phase 3 | Schizophrenia |
| Centanafadine XR | Phase 3 | Attention-deficit/Hyperactivity Disorder |
| Brexpiprazole, OPC-34712 | Phase 3 | Agitation Associated With |
| OCV-501 | Phase 2 | Acute Myeloid Leukemia |
| JNT-517 Tablet | Phase 3 | Phenylketonuria (PKU) |
| Delamanid + Bedaquiline + OPC-167832 10 mg | Phase 2 | Pulmonary TB |
| Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder |
| centanafadine capsule | Phase 3 | Attention Deficit/Hyperactivity Disorder |
| Probucol | Phase 3 | Hyperlipidemia |
| EB-1020 (Centanafadine) 328.8 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| Tolvaptan Oral Tablet | Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion |
| 0.3% OPA-15406 | Phase 3 | Atopic Dermatitis |
| 0.3% OPA-15406 Ointment | Phase 3 | Atopic Dermatitis (AD) |
| SEP-363856 75mg | Phase 3 | Schizophrenia |
| OPB-31121 | Phase 2 | Hepatocellular Carcinoma |
| OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
| OPC-41061 （Tolvaptan) | Phase 3 | Cardiac Edema |
| Sibeprenlimab 400 mg | Phase 3 | Immunoglobulin A Nephropathy |
| Latanoprost ophthalmic solution | Phase 3 | Glaucoma |
Price & technical context
3-month
+10.8%
6-month
+4.0%
12-month
+27.5%
52-wk range
$54.26–$77.53
vs 50-day MA
-1.3%
vs 200-day MA
+9.6%
Realized vol
26.6%
Max drawdown
-32.9%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OTSKF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.